SC
DFTX

Stempoint Capital’s Definium Therapeutics DFTX Stock Holding History

Stempoint Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.45M Sell
137,124
-188,359
-58% -$4.65M 1.11% 31
2026
Q1 		$6.15M Buy
+325,483
New +$5.52M 1.18% 29
2025
Q4 		– Sell
-76,875
Closed -$906K – 103
2025
Q3 		$906K Sell
76,875
-13,977
-15% -$130K 0.18% 64
2025
Q2 		$590K Buy
+90,852
New +$598K 0.19% 51

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Stempoint Capital's DFTX Position: Q2 2026 in Review

Stempoint Capital reduced its Definium Therapeutics (DFTX) stake by 58% in Q2 2026, selling an estimated $4.65M and leaving 137,124 shares worth $6.45M. The position accounts for 1.11% of the portfolio, ranked #31.

Stempoint Capital first reported a position in DFTX in Q2 2025 and has held it in 4 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Stempoint Capital held 137,124 shares of Definium Therapeutics worth $6.45M as of Q2 2026.
  • Stempoint Capital sold 188,359 Definium Therapeutics shares in Q2 2026, an estimated $4.65M.
  • Definium Therapeutics made up 1.11% of Stempoint Capital's portfolio in Q2 2026, its #31 holding.
  • Stempoint Capital first reported a position in Definium Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.